UBS Group
BHVN icon

UBS Group’s Biohaven BHVN Stock Holding History

UBS Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,000
Closed -$433K – 10261
2025
Q1 		$433K Buy
+18,000
New +$635K ﹤0.01% 5959

Other funds holding BHVN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's BHVN Position: Q1 2026 in Review

UBS Group increased its Biohaven (BHVN) stake by 20% in Q1 2026, buying an estimated $2.6M and bringing the position to 1,426,427 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3139.

UBS Group first reported a position in BHVN in Q4 2022 and has held it in 14 quarters since. The position peaked at $27.9M in Q4 2024. 275 funds tracked by Wall St. Rank hold BHVN as of Q1 2026.

  • UBS Group held 1,426,427 shares of Biohaven worth $12.1M as of Q1 2026.
  • UBS Group bought 238,069 Biohaven shares in Q1 2026, an estimated $2.6M.
  • Biohaven made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3139 holding.
  • UBS Group first reported a position in Biohaven in Q4 2022 and has held it in 14 quarters since.
  • UBS Group's Biohaven position peaked at $27.9M in Q4 2024.
  • 275 funds tracked by Wall St. Rank held Biohaven as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.